The Open Clinical Chemistry Journal最新文献_第2页

A Validated HPLC Method for the Determination of Vitamin K in Human Serum – First Application in a Pharmacological Study 高效液相色谱法测定人血清中维生素K含量-首次在药理学研究中的应用

The Open Clinical Chemistry Journal Pub Date : 2011-07-28 DOI: 10.2174/1874241601104010017

M. Marinova, D. Lütjohann, P. Westhofen, M. Watzka, O. Breuer, J. Oldenburg

{"title":"A Validated HPLC Method for the Determination of Vitamin K in Human Serum – First Application in a Pharmacological Study","authors":"M. Marinova, D. Lütjohann, P. Westhofen, M. Watzka, O. Breuer, J. Oldenburg","doi":"10.2174/1874241601104010017","DOIUrl":"https://doi.org/10.2174/1874241601104010017","url":null,"abstract":"Dietary phylloquinone (vitamin K1) is considered to be a major determinant of human vitamin K status. For this reason, measurements of plasma vitamin K concentrations provide a useful tool of vitamin K status in man. There is a growing interest in the role, biochemical function, and metabolism of vitamin K in vivo. A modified reversed phase-HPLC method with fluorescence detection after post-column zinc reduction in serum samples was validated for vitamin K analysis. Two human volunteers were investigated after p.o. and i.v. administration of 2 mg Konakion ® MM. Blood samples were collected periodically after administration and subjected to pharmacokinetic evaluation. High sensitivity, analytical recoveries, accuracy and calibration curves linearities could be reached. Our results showed an overall coefficient of variation of less than 10% for the intraand interday reproducibility, while the recovery ranged from 91% to 114 %. The limit of detection and quantification were 0.015 ng mL -1 and 0.15 ng mL -1 , respectively. Long-term stability was verified over a period of six months. The accuracy was proven by good results from external quality assurance. The observed pharmacokinetic differences indicate significant intraand inter-individual variance of vitamin K fate in the human body. This highly accurate, robust and reliable method is appropriate for the evaluation of vitamin K status in human serum. The ability to determine vitamin K has the potential to improve pharmacokinetic studies.","PeriodicalId":112973,"journal":{"name":"The Open Clinical Chemistry Journal","volume":"44 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2011-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123785537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Generating Evidence Based Interpretation of Hematology Screens via Anomaly Characterization 通过异常表征生成基于证据的血液学筛查解释

The Open Clinical Chemistry Journal Pub Date : 2011-03-01 DOI: 10.2174/1874241601104010010

G. David, L. Bernstein, R. Coifman

{"title":"Generating Evidence Based Interpretation of Hematology Screens via Anomaly Characterization","authors":"G. David, L. Bernstein, R. Coifman","doi":"10.2174/1874241601104010010","DOIUrl":"https://doi.org/10.2174/1874241601104010010","url":null,"abstract":"Introduction: We propose a simple, workable algorithm that provides assistance for interpreting any set of data from the screen of a blood analysis with high accuracy, reliability, and inter-operability with an electronic medical record. This has been made possible at least recently as a result of advances in mathematics, low computational costs, and rapid transmission of the necessary data for computation. Materials and Methods: The database used for this study is a file of 22,000 laboratory hemograms generated by two Beckman-Coulter Gen-S analyzers over a two month period in a 630 bed acute care facility in Brooklyn. All control samples, patient identifiers, and patients under 23 years old were stripped from the dataset. An experienced medical practitioner reviewed all of the data used in generating the algorithm described. The differential diagnoses were outlined prior to beginning the study, and preliminary studies were done to determine the reference ranges for each predictor. An algorithm for anomaly detection and classification via anomaly characterization is proposed. For each patient, the algorithm characterizes its anomalous profile and builds a differential metric to identify similar patients who are mapped into a classification. Results: The algorithm successfully classified patients into the diagnosis that were sufficient in sample size, and others are still under observation. The algorithm correctly classified the patients as follows: Microcytic Anemia - 99.63%, Normocytic Anemia - 98.03%, Mild SIRS - 73.42%, Thrombocytopenia - 99.52%, Leukocytopenia - 84.83%, Moderate / Severe SIRS - 96.69% and Normal - 93.18%. Discussion: This limited analysis of automated hematological results can be extended to the case of more complicated conditions than presented, and can be extended to a combination of chemistry, hematology, immunology, and other data.","PeriodicalId":112973,"journal":{"name":"The Open Clinical Chemistry Journal","volume":"95 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2011-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121208396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

C-Reactive Protein for the Enhanced Evaluation of the Systemic Inflammatory Response Syndrome (SIRS) c反应蛋白在系统性炎症反应综合征(SIRS)评估中的应用

The Open Clinical Chemistry Journal Pub Date : 2011-01-25 DOI: 10.2174/1874241601104010001

G. Pancer, E. Engelman, F. Hoque, M. E. Alam, J. Rucinski, L. Bernstein

引用次数: 7

Variation of Lp(a) Plasma Concentrations in Health and Disease~!2009-11-03~!2010-02-06~!2010-09-08~! 健康与疾病人群血浆Lp(a)浓度的变化2009-11-03 2010-02-06 2010-09-08

The Open Clinical Chemistry Journal Pub Date : 2010-09-08 DOI: 10.2174/1874241601003010072

R. Siekmeier, H. Scharnagl, Gert M. Kostner, T. Grammer, T. Stojakovic, W. März

{"title":"Variation of Lp(a) Plasma Concentrations in Health and Disease~!2009-11-03~!2010-02-06~!2010-09-08~!","authors":"R. Siekmeier, H. Scharnagl, Gert M. Kostner, T. Grammer, T. Stojakovic, W. März","doi":"10.2174/1874241601003010072","DOIUrl":"https://doi.org/10.2174/1874241601003010072","url":null,"abstract":"Lipoprotein(a) (Lp(a)) is an established risk marker of cardiovascular diseases which is independent from other risk markers. The main difference of Lp(a) compared to low density lipoprotein (LDL) is the apo(a) residue which is covalently bound to apoB. Apo(a) is a glycoprotein which underlies a large genetic polymorphism. The latter is caused by a variation of the kringle-IV-type-2 repeats of the protein which is characterized by a large structural homology to plasminogen. The Lp(a) plasma concentration in the population is highly skewed and determined to more than 90 % by genetic factors. In healthy subjects the Lp(a)-concentration is correlated to its synthesis and not to its metabolism. However, plasma concentrations of Lp(a) are also affected by different diseases (e.g. diseases of liver and kidney), hormonal factors (e.g. sexual steroids, glucocorticoids, thyroid hormones), individual and environmental factors (e.g. age, cigarette smoking) as well as pharmaceuticals (e.g. derivatives of nicotinic acid) and therapeutic procedures (lipid apheresis). Aim of this review was to describe the physiological regulation of Lp(a) as well as factors influencing its plasma concentration.","PeriodicalId":112973,"journal":{"name":"The Open Clinical Chemistry Journal","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2010-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120988022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Reference Ranges for Serum Biochemical Parameters among Healthy Cameroonians to Support HIV Vaccine and Related Clinical Trials 健康喀麦隆人血清生化参数参考范围支持HIV疫苗和相关临床试验

The Open Clinical Chemistry Journal Pub Date : 2010-06-18 DOI: 10.2174/1874241601003010066

G. Alemnji, J. Mbuagbaw, G. Této, S. Nkengafac, E. Folefac, N. Atems, B. Kwingwah, T. Asonganyi

{"title":"Reference Ranges for Serum Biochemical Parameters among Healthy Cameroonians to Support HIV Vaccine and Related Clinical Trials","authors":"G. Alemnji, J. Mbuagbaw, G. Této, S. Nkengafac, E. Folefac, N. Atems, B. Kwingwah, T. Asonganyi","doi":"10.2174/1874241601003010066","DOIUrl":"https://doi.org/10.2174/1874241601003010066","url":null,"abstract":"A valid scientific evaluation of the efficacy of human immunodeficiency virus (HIV) vaccines or antiretroviral drugs (ARV) includes measurement of changes in physiological parameters of subjects from known established baseline reference ranges. This study was designed to establish reference ranges for biochemical parameters among healthy adult Cameroonians to support planned HIV vaccine clinical trials and scaling up of ARV among AIDS patients. After informed consent, blood and urine samples were collected from a total of 576 adult Cameroonians and analyzed for the presence of underlying pathologies that may affect biochemical parameters. Samples from 501 of them were found eligible for the determination of reference biochemical parameters. After complete assay, the data were subjected to both parametric and non parametric statistics for analyses, with 2.5 and 97.5 percentiles considered as the lower and upper limits of reference ranges. There were 331 (66.1%) males and 170 (33.9%) females, with 359 (71.7%) and 142 (28.3%) of them residing in the urban and rural areas respectively. The ranges for biochemical parameters got were: SGOT: 8.7 40.7 IU/l ; SGPT: 5.2 29.1 IU/l ; Alkaline Phosphatase: 52.6 251.1 IU/l; Creatinine: 0.2 2.2 mg/dl; Total Protein : 46.9 107.4 g/l; Albumin : 30.1 65.2 g/l; Triglyceride : 0.1 3.5 g/l; HDL Cholesterol : 54.5 172.0 mg/dl; LDL Cholesterol: 12 – 190 mg/dl; Total Cholesterol 0.9 3.2 g/l; Total Bilirubin: 0.4 3.3 mg/dl; and Direct Bilirubin : 0.1 1.2 mg/dl. These ranges are compared to ranges presently used in various clinical laboratories in Cameroon.","PeriodicalId":112973,"journal":{"name":"The Open Clinical Chemistry Journal","volume":"111 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2010-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123319335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Editorial: Emerging Biomarkers for the Optimal Assessment of Global Cardiovascular Risk: where do we Stand?~!2009-11-10~!2009-12-10~!2010-04-08~! 社论:用于全球心血管风险最佳评估的新兴生物标志物:我们站在哪里?

The Open Clinical Chemistry Journal Pub Date : 2010-04-15 DOI: 10.2174/1874241601003020008

H. Milionis, M. Elisaf

引用次数: 0

Vitamin D Status and Cardiovascular Health: A 2009 Update~!2009-10-29~!2009-12-25~!2010-04-08~! 维生素D水平与心血管健康:2009年最新进展2009-10-29 2009-12-25 2010-04-08

The Open Clinical Chemistry Journal Pub Date : 2010-04-15 DOI: 10.2174/1874241601003010051

E. Michos, J. Reis, M. Melamed

引用次数: 0

Effect of Cardiovascular Drugs on the Plasma Levels of Lipoprotein- Associated Phospholipase A2 (Lp-PLA2)~!2009-10-29~!2009-12-28~!2010-04-08~! 心血管药物对血浆脂蛋白相关磷脂酶A2 (Lp-PLA2)水平的影响

The Open Clinical Chemistry Journal Pub Date : 2010-04-08 DOI: 10.2174/1874241601003010060

V. Tsimihodimos, A. Tselepis

{"title":"Effect of Cardiovascular Drugs on the Plasma Levels of Lipoprotein- Associated Phospholipase A2 (Lp-PLA2)~!2009-10-29~!2009-12-28~!2010-04-08~!","authors":"V. Tsimihodimos, A. Tselepis","doi":"10.2174/1874241601003010060","DOIUrl":"https://doi.org/10.2174/1874241601003010060","url":null,"abstract":"Several lines of evidence suggest that the lipoprotein-associated phospholipase A2 (Lp-PLA2) plays an impor- tant role in the pathogenesis of atherosclerotic disease. From a pathophysiological point of view the enzyme bound to apolipoprotein-B-containing lipoproteins (which corresponds to more than 90% of plasma enzymatic activity) may play a proatherogenic role since it generates lysophosphatidylcholine and oxidized fatty acids, molecules that have been shown to promote atherogenesis. On the other hand, the enzyme associated with high-density lipoprotein (HDL) may play an antiatherogenic role since it protects low-density lipoprotein (LDL) from oxidation and diminishes the biological func- tions of oxidized LDL. Several large-scale, prospective studies have shown that both plasma Lp-PLA2 mass and activity represent important predictors of future cardiovascular risk in primary and secondary prevention populations. In this re- view, we summarize the current knowledge on the effect of drugs used in the treatment of cardiovascular disease on the plasma levels of Lp-PLA2. This information may help clinicians to design safe and effective therapeutic strategies for the prevention and treatment of atherosclerotic disease. Keyword: Lipoprotein-associated phospholipase A2, cardiovascular drugs, statins, fibrates.","PeriodicalId":112973,"journal":{"name":"The Open Clinical Chemistry Journal","volume":"53 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2010-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114982789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Pitfalls in the Evaluation of Uric Acid as a Risk Factor for Vascular Disease~!2009-10-29~!2009-12-23~!2010-04-08~! 尿酸作为血管疾病危险因素评价中的误区2009-10-29 2009-12-23 2010-04-08

The Open Clinical Chemistry Journal Pub Date : 2010-04-08 DOI: 10.2174/1874241601003010044

K. Tziomalos, V. Athyros, A. Karagiannis, D. Mikhailidis

{"title":"Pitfalls in the Evaluation of Uric Acid as a Risk Factor for Vascular Disease~!2009-10-29~!2009-12-23~!2010-04-08~!","authors":"K. Tziomalos, V. Athyros, A. Karagiannis, D. Mikhailidis","doi":"10.2174/1874241601003010044","DOIUrl":"https://doi.org/10.2174/1874241601003010044","url":null,"abstract":"The association between serum uric acid (SUA) levels and the risk for vascular disease is controversial. Several studies in the general population suggested that elevated SUA levels are independently related to increased vascular mor- bidity and mortality. However, in other studies this relationship was not significant when other vascular risk factors were considered. Some evidence also suggests that uric acid might be implicated in the development of hypertension, renal dis- ease and insulin resistance. We review the epidemiological data on the relationship between SUA levels and vascular dis- ease and summarize the potential adverse vascular effects of uric acid. We also discuss the associations of SUA levels with established vascular risk factors and the potential benefits of lowering SUA concentration. It is unclear whether uric acid is a causal risk factor for vascular disease. Until more conclusive data are available, patients with elevated SUA lev- els should be evaluated for the presence of more established risk factors (including type 2 diabetes mellitus, metabolic syndrome and chronic kidney disease) and treatment should be targeted against these factors.","PeriodicalId":112973,"journal":{"name":"The Open Clinical Chemistry Journal","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2010-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131007552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Vitamin D status and cardiovascular health: A 2009 update 维生素D状况与心血管健康:2009年更新

The Open Clinical Chemistry Journal Pub Date : 2010-04-08 DOI: 10.2174/1874241601003020051

E. Michos, J. Reis, M. Melamed

引用次数: 10